Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, has signed a $3 million agreement with the Two2Ten Foundation to support the expansion of its Sequence Ablation Therapeutics (SAT) platform into oncology. The funding will support preclinical research applying Seek Labs’ programmable therapeutic approach to cancer, with the aim of creating new options for patients underserved by existing treatments. The collaboration reflects a shared belief that existing treatments leave too many patients without effective options and that advancing cancer care requires investment in new therapeutic approaches. The Foundation's support will advance research into SAT candidates and their delivery. The program will evaluate SAT in preclinical cancer models, generating evidence to inform the platform’s development in oncologology.
Yayınlanan : 4 saat önce ile GlobeNewswire içinde Health Tech Science
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder SALT LAKE CITY, Oct. 26, 2026 (GLO... [4393 symbols]
